Facilitated subcutaneous immunoglobulin 10% for CIDP: interim results from a long-term safety and tolerability study

被引：0
|
作者：
Hadden, R. [1 ]
Andersen, H. [2 ]
Bril, V. [3 ]
Basta, I. [4 ]
Rejdak, K. [5 ]
Djordjevic, G. [6 ]
Greco, E. [7 ]
Hasan, S. [7 ]
French, J. [7 ]
Yel, L. [7 ]
Ay, H. [7 ]
机构：
[1] Kings Coll Hosp London, Dept Neurol, London, England
[2] Aarhus Univ, Aarhus, Denmark
[3] Univ Toronto, Univ Hlth Network, Ellen & Martin Prosserman Ctr Neuromuscular Dis, Toronto, ON, Canada
[4] Univ Belgrade, Univ Clin Ctr Serbia, Neurol Clin, Fac Med, Belgrade, Serbia
[5] Med Univ Lublin, Dept Neurol, Lublin, Poland
[6] Univ Clin Ctr Nis, Neurol Clin, Nish, Serbia
[7] Takeda Dev Ctr Amer Inc, Cambridge, MA USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2023年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPR-244
引用
收藏
页码：286 / 286
页数：1
相关论文
共 50 条
  • [1] HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN 10% FOR CIDP: FINAL RESULTS FROM A LONG-TERM SAFETY AND TOLERABILITY STUDY
    Hadden, Robert
    Andersen, Henning
    Bril, Vera
    Basta, Ivana
    Rejdak, Konrad
    Duff, Kim
    Greco, Erin
    Hasan, Shabbir
    Anderson-Smits, Colin
    Ay, Hakan
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2024, 29 : S78 - S79
  • [2] Long-term safety and tolerability of hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: Results from the ADVANCE-CIDP 3 trial
    Hadden, Robert D. M.
    Andersen, Henning
    Bril, Vera
    Basta, Ivana
    Rejdak, Konrad
    Duff, Kim
    Greco, Erin
    Hasan, Shabbir
    Anderson-Smits, Colin
    Ay, Hakan
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2024, 29 (04) : 441 - 452
  • [3] Interim analysis of a postauthorization safety study on long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in primary immunodeficiency disease in Europe
    Ellerbroek, P. M.
    van Paassen, P.
    Hanitsch, L.
    Plebani, A.
    Schmidt, R. E.
    van Hagen, P. M.
    Wang, P.
    Fielhauer, K.
    Leibl, H.
    Yel, L.
    SWISS MEDICAL WEEKLY, 2019, : 17S - 17S
  • [4] Final Analysis of Long-Term Safety of Facilitated Subcutaneous Immunoglobulin Across the Age Range: Results from a Postauthorization Study
    Ellerbroek, Pauline
    Witte, Torsten
    Lougaris, Vassilios
    Chen, Jie
    Nagy, Andras
    Mccoy, Barbara
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2022, 42 (SUPPL 1) : S49 - S50
  • [5] LONG-TERM SAFETY OF FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN: INSIGHTS FROM A POSTAUTHORIZATION SAFETY STUDY IN PRIMARY IMMUNODEFICIENCY DISEASES
    Rubinstein, Arye
    Patel, Niraj
    Wedner, H. James
    Wasserman, Richard
    Gupta, Sudhir
    Fielhauer, Katharina
    Chavan, Shailesh
    Yel, Leman
    MUSCLE & NERVE, 2021, 64 : S62 - S62
  • [6] Long-term Safety of Facilitated Subcutaneous Immunoglobulin Treatment in Patients With Primary Immunodeficiency Diseases: Interim Analysis from a Post-authorization Safety Study
    Rubinstein, Arye
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB73 - AB73
  • [7] Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization study
    Ellerbroek, Pauline M.
    Hanitsch, Leif G.
    Witte, Torsten
    Lougaris, Vassilios
    van Hagen, P. Martin
    Paassen, Pieter van
    Chen, Jie
    Fielhauer, Katharina
    McCoy, Barbara
    Nagy, Andras
    Yel, Leman
    IMMUNOTHERAPY, 2024, 16 (10) : 679 - 691
  • [8] EUROPEAN POSTAUTHORIZATION SAFETY STUDY ON LONG-TERM HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN IN PRIMARY IMMUNODEFICIENCY DISEASES: INTERIM ANALYSIS
    Ellerbroek, Pauline M.
    van Paassen, Pieter
    Hanitsch, Leif
    Plebani, Alessandro
    Schmidt, Reinhold E.
    van Hagen, P. Martin
    Wang, Ping
    Fielhauer, Katharina
    Leibl, Heinz
    Chavan, Shailesh
    Yel, Leman
    MUSCLE & NERVE, 2020, 62 : S67 - S68
  • [9] Long-term safety of facilitated subcutaneous immunoglobulin treatment in pregnant women with primary immunodeficiency diseases: results from a registry study
    Borte, Michael
    Raffac, Stefan
    Hrubisko, Martin
    Jahnz-Rozyk, Karina
    Garcia, Enrique
    McCoy, Barbara
    Chavan, Shailesh
    Nagy, Andras
    Yel, Leman
    IMMUNOTHERAPY, 2022, 14 (08) : 609 - 616
  • [10] Interim Analysis of a Post-authorisation Safety Study on the Long-Term Safety of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in Patients with Primary Immunodeficiency Diseases in Europe
    Ellerbroek, P. M.
    Van Paassen, P.
    Hanitsch, L.
    Plebani, A.
    Schmidt, R. E.
    Van Hagen, P. M.
    Wang, P.
    Fielhauers, K.
    Leibls, H.
    Chavan, S.
    Yel, L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 402 - 403
12345